Treatment of Follicular Lymphoma with Early Relapse (POD24) and High Tumor Burden
Early disease progression within 24 months of starting treatment — known as POD24 — identifies a high-risk subset of follicular lymphoma patients. When POD24 coincides with high tumor burden, active rescue treatment is required.
Clinical Scenario
Approximately 15–20% of patients with follicular lymphoma do not respond adequately or experience early relapse, defined as progression of disease within 24 months (POD24) from the start of treatment. Patients experiencing early relapse are treated when they present with a high tumor burden.
POD24 with high tumor burden represents a high-risk clinical situation that warrants prompt, structured intervention.
Rescue Treatment Approach
The conventional approach involves rescue immunochemotherapy using a regimen different from the one used initially. The specific regimen is selected based on what was given in the first-line setting and on individual patient factors such as age, fitness, and comorbidities. Options for frail or elderly patients differ from those for transplant-eligible individuals.
Clinical goal: achieve at least a partial response after rescue induction — enabling further treatment decisions based on response and patient eligibility.
References
DOI: 10.3390/cancers18030395
- Approximately 15–20% do not respond or experience early relapse, defined as progression of disease within 24 months (POD24) from the start of treatment.
- Patients experiencing early relapse should be treated if they have a high tumor burden (1B).
- Immunochemotherapy, utilizing a regimen different from the first-line regimen, remains the conventional option (1C).
- POD24 patients who respond to rescue therapy (achieving at least PR) may benefit from intensification with ASCT, if eligible based on age and general health status (1B).
View source ↗